Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 5 min ago
Peer-reviewedLicence not statedJournal of Diabetes Science and Technology

Multisystem Outcomes of GLP-1 Receptor Agonists Versus Active Comparators in Type 2 Diabetes: A Multicenter Target Trial Emulation

  • Rohit Vashisht1,2
  • Sanket S. Dhruva3,4
  • Ayan Patel1,2
  • Lisa Dahm2
  • Pagan Morris2
  • David Gonzalez2
  • Rob Follett2
  • Marina Sirota1
  • Karandeep Singh5
  • Suneil Koliwad6
  • Cora Han2
6 affiliations
  1. 1Bakar Computational Health Sciences Institute, University of California, San Francisco, USA
  2. 2Center for Data-driven Insights and Innovation, University of California Health, Oakland, USA
  3. 3Section of Cardiology, Department of Medicine, School of Medicine, University of California, San Francisco, USA
  4. 4San Francisco Veterans Affairs Health Care System, CA, USA
  5. 5Digital Health Innovation, University of California San Diego Health, USA
  6. 6Division of Endocrinology and Metabolism, University of California, San Francisco, USA
Read full textDOICite

Related

  1. Chemotherapy outcomes in human epidermal growth factor receptor 2-low, hormone receptor-positive metastatic breast cancer: Insights from the French multicenter ESME database.
    William Jacot, Pauline Macouillard, Suyuan Zhang +11
    Breast (Edinburgh, Scotland)Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  2. Individual Angiotensin Receptor Blockers and Risk of Dementia: A Target Trial Emulation Study
    N. H. Hampilos, T. R. Campion, E. Sholle +4
    medRxivPreprintAll rights reservedFull textNeurologymedRxiv
  3. GLP-1 receptor agonist initiation and newly recorded ankylosing spondylitis diagnoses in type 2 diabetes: a target trial emulation
    Yu-Chen Lu, Tzu-Hao Li, Ya-Fang Liu +1
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textEndocrinology & metabolismCrossref
  4. Selecting Vehicle Comparators in Dry Eye Disease Clinical Trials: Implications for Efficacy and Safety Assessment and Regulatory Outcomes
    Isabella Tunon-Robinson, Suzanne Zheng, Cathy Zhao +2
    Ophthalmology and TherapyPeer-reviewedCC BY-NCFull textEpidemiology & public healthDOAJ
  5. Comparative Neoplasm Risk of Mirabegron and Antimuscarinic Therapy in Overactive Bladder: A Multicenter Target Trial Emulation
    Fu-Shun Yen, James Cheng-Chung Wei, Chih-Cheng Hsu +4
    CancersPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC

Cite

BibTeXRIS
BibTeX
@article{vashisht2026multisystem,
  title = {{Multisystem Outcomes of GLP-1 Receptor Agonists Versus Active Comparators in Type 2 Diabetes: A Multicenter Target Trial Emulation}},
  author = {Rohit Vashisht and Sanket S. Dhruva and Ayan Patel and Lisa Dahm and Pagan Morris and David Gonzalez and Rob Follett and Marina Sirota and Karandeep Singh and Suneil Koliwad and Cora Han},
  journal = {Journal of Diabetes Science and Technology},
  year = {2026},
  month = oct,
  doi = {10.1177/19322968261498914},
  url = {https://doi.org/10.1177/19322968261498914},
}
RIS
TY  - JOUR
TI  - Multisystem Outcomes of GLP-1 Receptor Agonists Versus Active Comparators in Type 2 Diabetes: A Multicenter Target Trial Emulation
AU  - Rohit Vashisht
AU  - Sanket S. Dhruva
AU  - Ayan Patel
AU  - Lisa Dahm
AU  - Pagan Morris
AU  - David Gonzalez
AU  - Rob Follett
AU  - Marina Sirota
AU  - Karandeep Singh
AU  - Suneil Koliwad
AU  - Cora Han
PY  - 2026
DA  - 2026/10/28
JO  - Journal of Diabetes Science and Technology
DO  - 10.1177/19322968261498914
UR  - https://doi.org/10.1177/19322968261498914
SN  - 1932-2968
ER  -